Batten disease (CLN8)

Overview

Batten disease, specifically the form associated with changes in the CLN8 gene, is a rare genetic condition that primarily impacts the nervous system. It is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs) [PMID:31973686]. These conditions are characterised by the progressive accumulation of fatty substances (lipofuscins) within the cells, especially in the brain, leading to cell damage and neurological problems. Batten disease (CLN8) is an inherited condition, meaning it is passed down through families.

Symptoms & clinical features

Individuals with Batten disease (CLN8) typically experience a range of progressive neurological symptoms. The onset and severity can vary, but generally include developmental regression, where previously acquired skills are lost. Seizures are a common feature, and their frequency and type may change over time [PMID:16149176]. Other symptoms can include difficulties with balance and coordination (ataxia), movement disorders, and a decline in cognitive abilities. Visual problems are also often observed in NCLs, though their specific presentation can differ between types. The progressive nature of the condition means that symptoms tend to worsen over time.

Video: Genetics 101

Affected organs

The primary organ affected by Batten disease (CLN8) is the brain, where the accumulation of waste materials leads to widespread neuronal damage. This damage underlies the neurological symptoms observed. Other parts of the nervous system, including the eyes, can also be affected, contributing to visual impairment. While the disease is largely neurological, the cellular dysfunction is widespread, impacting cells throughout the body due to the accumulation of lipofuscin, though the most prominent clinical features are neurological.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Batten disease (CLN8) is a severe, progressive neurodegenerative disorder. The age of onset can vary, with symptoms typically appearing in late infancy, childhood, or early adolescence, depending on the specific CLN8 variant [PMID:16149176]. Once symptoms begin, they generally worsen progressively over several years, leading to significant disability. The severity and rate of progression can differ between individuals. Due to the progressive and severe nature of the neurological decline, this condition significantly impacts quality of life and is life-limiting. Exact prevalence figures are not well established, but it is considered a rare disease.

Genetic causes

Batten disease (CLN8) is caused by pathogenic variants in the CLN8 gene. This gene provides instructions for making a transmembrane protein that is thought to be involved in the movement of materials, particularly lipids, within cells. This protein is especially important for the function of the endoplasmic reticulum (ER) and ER-Golgi intermediate compartment (ERGIC) [PMID:31973686]. The ER is a network within the cell that plays a crucial role in protein synthesis and lipid metabolism. When the CLN8 protein is altered due to a gene variant, it can disrupt these cellular processes, leading to the accumulation of lipofuscin within cells. This build-up is particularly damaging to neurons, resulting in the neurodegenerative features of the disease.

• CLN8
  CLN8 transmembrane ER and ERGIC protein
  The CLN8 gene provides instructions for a protein thought to be involved in transport within cells, particularly in the endoplasmic reticulum, and is associated with Batten disease.

Inheritance pattern

Batten disease (CLN8) has an autosomal recessive inheritance pattern. This means that an individual must inherit two altered copies of the CLN8 gene - one from each parent - to develop the condition. If a person inherits only one altered copy and one typical copy of the gene, they are considered a 'carrier' and generally do not show symptoms of the disease. When both parents are carriers, there is a 1 in 4 (25%) chance with each pregnancy that their child will inherit two altered copies and develop Batten disease. There is also a 2 in 4 (50%) chance that their child will be a carrier, and a 1 in 4 (25%) chance that their child will inherit two typical copies of the gene.

Diagnosis & testing

Diagnosis of Batten disease (CLN8) typically begins with a clinical evaluation based on the presenting symptoms, such as developmental regression, seizures, and visual impairment. Further investigation may involve brain imaging (such as MRI), electroencephalograms (EEGs) to assess brain activity, and specialised tests to measure enzyme levels or look for characteristic cellular inclusions. The definitive diagnosis is confirmed through genetic testing, which identifies pathogenic variants in the CLN8 gene. In the UK, genetic testing for inherited neurological disorders is often accessed via the NHS Genomic Medicine Service (GMS), with R-codes such as R421 (Lysosomal disorders) potentially being relevant. Referrals for genetic testing are usually made by a paediatric neurologist or a clinical geneticist.

Management & lifestyle

Management for Batten disease (CLN8) is primarily supportive and aims to manage symptoms and improve quality of life. This can involve medication to control seizures, therapies to help with movement and development (such as physiotherapy and occupational therapy), and nutritional support. Regular monitoring by a multidisciplinary team, including neurologists, ophthalmologists, and allied health professionals, is generally recommended. Individuals and families are typically supported through the NHS, with specialist care centres providing comprehensive management plans. Genetic counsellors can provide essential information about the inheritance pattern and implications for family planning. Research is ongoing into potential treatments for NCLs, including gene therapies, but these are not yet routinely available.

UK care pathway

In the UK, individuals suspected of having an inherited neurological condition like Batten disease (CLN8) can access care through the NHS. The process often involves a referral from a GP or specialist to a clinical genetics service. This may lead to genetic testing via the NHS Genomic Medicine Service, guided by specific R-codes for rare diseases. Genetic counsellors play a vital role, offering support and information regarding diagnosis, inheritance, and family implications. Care is typically managed by specialist paediatric or adult neurology teams, often in conjunction with other healthcare professionals.

Related conditions

Batten disease (CLN8) is one of several types of neuronal ceroid lipofuscinosis (NCL). While they share a common feature of lipofuscin accumulation and progressive neurodegeneration, the specific genes involved, age of onset, and symptom presentation can vary between the different NCL types. Other NCLs are caused by variants in genes such as CLN1, CLN2, CLN3, and CLN6, for example. Differentiating between these conditions requires careful clinical assessment and specific genetic testing to identify the causative gene.

Frequently asked questions